AORT - Artivion, Inc.
Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction to ac
HERZLIYA, Israel--(BUSINESS WIRE)-- #aortaEd--Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction to acquire the company. This strategic milestone follows the April 2026 U.S. Food and Drug Administration (FDA) PMA approval of the NEXUS® Aortic Arch System, the first off-the-shelf endovascular solution designed to treat aortic arch disease, including chronic aortic dissections, in patients at high risk for.
ATLANTA, May 18, 2026 Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed the acquisition of its long-standing partner Endospan Ltd. ("Endospan"), a pioneer in the endovascular repair of aortic arch disease and developer of the NEXUS® Aortic Arch System.
Artivion delivers advanced cardiovascular and vascular solutions to healthcare providers worldwide through its proprietary medical devices.
MILWAUKEE, May 11, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Artivion (NYSE: AORT). The investigation results from inaccurate statements Artivion may have made regarding its financial statements, business operations and prospects.
Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript
Artivion NYSE: AORT executives said the company delivered double-digit revenue and adjusted EBITDA growth in the first quarter of 2026, while also lowering its full-year revenue outlook due primarily to softer stent graft trends and timing around U.S. AMDS account stocking.
Artivion (AORT) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.06 per share a year ago.
First Quarter & Recent Business Highlights: Achieved revenue of $116.3 million in the first quarter of 2026 versus $99.0 million in the first quarter of 2025, an increase of 18% on a GAAP basis and 12% on a non-GAAP constant currency basis Net income for the first quarter of 2026 was $1.4 million, or $0.03 per fully diluted share, and non-GAAP net income was $4.2 million, or $0.08 per fully diluted share Adjusted EBITDA increased 26% to $22.1 million in the first quarter of 2026 compared to $17.5 million in the first quarter of 2025 Announced U.S. FDA PMA Approval of the NEXUS Aortic Arch System for the treatment of aortic arch disease, including chronic aortic dissections Exercised option to acquire Endospan for an upfront purchase price of $135 million, net of previously extended loans ATLANTA, May 7, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the first quarter ended March 31, 2026. "In the first quarter of 2026, we achieved 12% constant currency revenue growth and 26% adjusted EBITDA growth, reflecting continued execution of our strategy to deliver long-term, profitable performance with an expanding and clinically differentiated product portfolio.
ATLANTA, April 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2026 financial results will be released on Thursday, May 7, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.
Pressure BioSciences (OTCMKTS:PBIO - Get Free Report) and Artivion (NYSE: AORT - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation. Earnings and Valuation This table compares Pressure BioSciences
AORT jumps after FDA approves NEXUS Aortic Arch System, unlocking a potential Endospan acquisition and advancing minimally invasive care for high-risk patients.
Artivion (AORT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Endospan's NEXUS branched endovascular stent graft system shown to effectively treat aortic arch disease, including chronic aortic dissections ATLANTA, April 7, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the NEXUS® Aortic Arch System, developed by Endospan Ltd. ("Endospan"), Artivion's long-standing partner.
SG Americas Securities LLC boosted its position in shares of Artivion, Inc. (NYSE: AORT) by 578.4% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,030 shares of the company's stock after acquiring an additional 33,277 shares during the period. SG Americas
Artivion, Inc. (NYSE: AORT - Get Free Report)'s stock price gapped down prior to trading on Thursday. The stock had previously closed at $36.62, but opened at $33.60. Artivion shares last traded at $33.1650, with a volume of 15,025 shares changing hands. Wall Street Analysts Forecast Growth Several research firms have recently issued reports on
Shares of Artivion, Inc. (NYSE: AORT - Get Free Report) have received an average rating of "Moderate Buy" from the eight research firms that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month
ATLANTA, March 3, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate virtually at the upcoming Oppenheimer 36th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 9:20 a.m.
Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript
Artivion (AORT) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to break-even earnings per share a year ago.